Elica

Please email: Niccolò Pignatelli, Damian Severgnini

Long-only biotech fund with a concentrated portfolio of listed clinical stage companies developing therapeutics for unmet clinical needs with potential annual sales >$1bn

Powered by secular mega-trends

Ageing population

By 2050 the global **population over 60 will double**

Big-pharma patent cliff

~$200bn in annual sales will lose exclusivity by 2030

New frontiers

Human genome sequencing cost **down 10x in 10 years**

Team

Specialists to seize the opportunity

Niccolò Pignatelli MEng SM | Manager

Imperial College London, MIT

Ines Malenica PhD | Scientific Analyst

Humanitas University, Université Paris-Saclay

Damian Severgnini | Business Dev.

INSEAD, LSE, King's College London

Pipeline

Developing more drugs than any pharma company

Drugs in clinical development



Exits

14 successful exits since 2022

Company	Acquirer	Disease Area
Horizon	Amgen	Auto-immunity
Iveric Bio	Astellas	Ophthalmology
Chinook Therapeutics	Novartis	Nephrology
Mirati Therapeutics	Bristol Myers Squibb	Oncology
ImmunoGen	AbbVie	Immuno-oncology
Icosavax	AstraZeneca	Virology
SpringWorks Therapeutics	Merck	Oncology
Verona Pharma	Merck	Pulmonology
89bio	Roche	Metabology
Akero	Novo Nordisk	Metabology
Avidity Biosciences	Novartis	Myology
Cidara Therapeutics	Merck	Virology
Ventyx Biosciences	Lilly	Inflammation
Day One Biopharmaceuticals	Servier	Oncology

Since UCITS fund inception

Performance

Past performance is not indicative of future returns. Strategy performance is unaudited.

The Elica strategy was launched on 20th January 2022 and then opened to external investors via a UCITS fund on 10th September 2024.
N.B.: Elica does not have a benchmark.

%	2024 *from 10/9*	2025	2026 *to 6/3*	Total *from fund inception 10/9/2024*	Annualised *from fund inception 10/9/2024*	***Total*** *from strategy inception on 20/1/2022*
Elica USD-I	**-5.9**	**37.1**	**6.2**	**36.9**	**23.4**	***65.2***
Nasdaq Biotech Index	-10.3	34.1	1.4	20.8	13.5	44.8
NYSE Biotech Index	-8.9	29.0	-0.7	15.6	10.2	31.7
S&P Biotech Index	-8.3	36.4	1.7	27.2	17.4	36.7